ASCO 2015 Highlights

Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

GASTO 1001: a Phase 2 Trial of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin in Patients with Unresectable Stage III Lung Adenocarcinoma

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

ASCEND-3: a Phase 2 Study of Ceritinib in ALK Inhibitor-Naïve Adult Patients with ALK+ NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

PD-L1, PD-1, and CTLA-4 as Prognostic Biomarkers in Resected NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

First-line Monotherapy with Nivolumab in Advanced NSCLC: Safety, Efficacy, and Correlation of Outcomes with PD-L1 Expression

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Results from the GENIUS Trial: Maintenance Therapy with Gefitinib/Pemetrexed vs Pemetrexed for Metastatic Lung Adenocarcinoma with No Sensitizing EGFR Mutation

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Subgroup Analysis from REVEL: Safety by Histology and Efficacy in Nonsquamous NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Docetaxel plus Ramucirumab vs Docetaxel plus Placebo as Second-line Treatment for Advanced NSCLC: a Phase 2 Multicenter Trial in Japan

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Results from KEYNOTE-021 Cohort D: a Phase 1 Study of Pembrolizumab plus Ipilimumab as Second-line Therapy for Advanced NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Page 194 of 329